Ascendis Pharma A/S
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ASND in the last 30 days.
See all $ASND insider activity →Analysts from Barclays and J.P. Morgan maintained Buy ratings on Merck (MRK), Tarsus Pharmaceuticals (TARS), and Ascendis Pharma (ASND). MRK has a $150 PT from Barclays, $180 from Scotiabank. TARS has a $110 PT from Barclays, $116 from Goldman Sachs. ASND has a $318.31 avg PT. All stocks have upside potential according to analysts.
Ascendis Pharma (ASND) will present data at ASBMR 2026 showing normalization of bone mass in hypoparathyroidism patients treated with palopegteriparatide over five years. The company will also share updates on navepegritide for achondroplasia, including improved growth and physical functioning in children.
Ascendis Pharma (ASND) will present data on its hypoparathyroidism and achondroplasia programs at ASBMR 2026. Key updates include 5-year data from TransCon PTH trials showing normalized bone mass and microarchitecture. The company also plans to share results from its achondroplasia trials, including growth and physical function improvements.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ASND (Ascendis Pharma A/S). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ASND coverage spans corporate actions, financial news and market movers.
Analyst reaffirmation and elevated targets suggest upside for ASND.
Positive long‑term trial results suggest strong commercial potential for TransCon PTH, likely driving buying interest.
Positive trial data likely lifts ASND as investors anticipate regulatory progress.
The rights reclaim and buyback could lift valuation if execution risk is managed, but short‑term momentum is negative.
The rights reversion adds development risk and funding needs, likely pressuring the stock lower despite the buyback.
AlphAI scores every news story that mentions ASND with an AI model for sentiment and relevance, and aggregates insider trades from Ascendis Pharma A/S's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts from Barclays and J.P. Morgan maintained Buy ratings on Merck (MRK), Tarsus Pharmaceuticals (TARS), and Ascendis Pharma (ASND). MRK has a $150 PT from Barclays, $180 from Scotiabank. TARS has a $110 PT from Barclays, $116 from Goldman Sachs. ASND has a $318.31 avg PT. All stocks have upside potential according to analysts.
2 min readAscendis Pharma (ASND) will present data at ASBMR 2026 showing normalization of bone mass in hypoparathyroidism patients treated with palopegteriparatide over five years. The company will also share updates on navepegritide for achondroplasia, including improved growth and physical functioning in children.
3 min readAscendis Pharma (ASND) will present data on its hypoparathyroidism and achondroplasia programs at ASBMR 2026. Key updates include 5-year data from TransCon PTH trials showing normalized bone mass and microarchitecture. The company also plans to share results from its achondroplasia trials, including growth and physical function improvements.
2 min readAscendis Pharma (ASND) has regained full control of its TransCon technology in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company also authorized a $400 million share repurchase program. Despite this, the stock has declined 9.9% over 30 days and 8.1% year-to-date. Analysts estimate a fair value of $313, suggesting the stock may be 28% undervalued, but execution risks remain.
2 min readAscendis Pharma (ASND) fell 6.1% as investors reacted to the company taking back rights to its metabolic and cardiovascular programs from Novo Nordisk. The move adds development burden and execution risk, despite a $400 million share repurchase plan. Analysts downgraded the stock, citing increased risk.
2 min readAscendis Pharma (ASND) authorized a $400M share buyback. Q2 2025 saw €315M product revenue, up 105% YoY, with €220M operating profit. Cash reserves grew to €812M. Buyback is discretionary, dependent on market conditions. YORVIPATH drove most revenue, while SKYTROFA and YUVIWEL contributed less. Costs increased due to expansion and R&D.
2 min readAscendis Pharma (ASND) and BioMarin (BMRN) settled a patent dispute, with ASND paying BMRN royalties on Yuviwel sales. ASND rose 6% and BMRN 1%. Analysts adjusted targets but kept ratings unchanged, citing legal clarity and growth prospects.
2 min readAscendis Pharma (ASND) will regain exclusive rights to metabolic and cardiovascular TransCon products, including TransCon Semaglutide, after ending its collaboration with Novo Nordisk (NVO). The move grants ASND more control but also shifts development costs and risks. ASND plans to initiate multiple programs, but clinical success and differentiation remain uncertain.
2 min readAscendis Pharma (ASND) fell 13% to $230.28 after authorizing a $400M share repurchase program. The stock traded between $230.18 and $257.53 with high volume. Repurchases may occur via various methods, subject to market conditions. The 52-week range is $186.05 to $282.15.
1 min readAscendis Pharma (ASND) fell 10.9% after ending a metabolic and cardiovascular collaboration, reverting rights to TransCon semaglutide. Analysts downgraded the stock, despite a $400M share buyback plan. Investors may be reassessing the program's value and development path.
2 min read
